Éric Béliveau, PhD
The Infectious Diseases and Immunity in Global Health Program (IDIGH) unites expertise, resources and research strengths in infectious diseases, immunology and global health across three domains. It comprises 18 laboratory-based research groups at the Centre for Translational Biology, 16 groups with a focus on epidemiology and health outcomes research from the Centre for Outcomes Research and Evaluation, and 25 groups conducting clinical research associated with the Centre for Innovative Medicine.
The program is designed to act as a catalyst for innovative research and establish discovery pipelines in select diseases. It also aims to train the next generation of scientists in biomedical, clinical, and health outcomes research, and to facilitate capacity-building in resource-poor countries that are disproportionately affected by diseases of poverty (e.g., tuberculosis, leprosy, human immunodeficiency virus (HIV), and neglected tropical diseases). The synergistic interaction of methodological approaches ensures that research and training conducted within the program is interdisciplinary and multidisciplinary, with a strong translational focus.
Review our research highlights and publications in the 2022 RI-MUHC Annual Report.
Researchers in the IDIGH program are involved in a multitude of research initiatives, including:
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) – an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 460 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC.